Gouty Arthritis: A Novel Therapeutic Approach for Highly Resistant Patients

Volume 8, Issue 2, April 2023     |     PP. 124-129      |     PDF (117 K)    |     Pub. Date: March 19, 2023
DOI: 10.54647/cm321045    66 Downloads     3008 Views  

Author(s)

Stephen Soloway, Inspira Heath Network Chairman Of Rheumatology,Department of Internnal Medicine, Aland Islands
Alyxandra Soloway, Inspira Health Network- Rheumatology, Aland Islands
Tyler G. Chin, Ursinius College ; Biology/Medicine, Aland Islands
Joseph Colombo, Stephen Soloway , MD, Rheumatology, Aland Islands

Abstract
Introduction. Gouty arthritis normally is well controlled. Under extreme circumstances patients for various reasons may have to use Pegloticase (Krystexxa). About 30% of patients on Krystexxa develop immunogenicity or tolerance to the medication rendering it useless, and with use of immunosuppressants this tolerance can be blunted in almost 50% of patients, which leaves 15% with dialysis. To our knowledge, the first cases of severe gout and intolerance of Krystexxa, who were then placed on Allopurinol (Zyloprim) and Febuxostat (Uloric) and received a considerable benefit are presented in this clinical study.
Methods. Three patients were diagnosed with Gouty arthritis and found intolerant of Krystexxa. Allopurinol 600mg daily with a taper of corticosteroids, history dependent, were introduced. Patients found to have uric acid levels that remained high were prescribed Uloric 40mg, titrated to 80mg as needed.
Results. All patients’ uric acid levels were reduced from >12mg/dL to < 4 mg/dL and maintained at the lower levels.
Conclusion. In cases of severe gout and intolerance of Krystexxa, Allopurinol and Uloric may provide considerable benefit.

Keywords
Gout, Arthritis, Polymyalgia Rheumatica, Psoriatic Arthritis, Pegloticase (Krystexxa), Allopurinol (Zyloprim), Febuxostat (Uloric)

Cite this paper
Stephen Soloway, Alyxandra Soloway, Tyler G. Chin, Joseph Colombo, Gouty Arthritis: A Novel Therapeutic Approach for Highly Resistant Patients , SCIREA Journal of Clinical Medicine. Volume 8, Issue 2, April 2023 | PP. 124-129. 10.54647/cm321045

References

[ 1 ] Wilson L, Saseen JJ. Gouty Arthritis: A Review of Acute Management and Prevention. Pharmacotherapy. 2016 Aug;36(8):906-22. doi: 10.1002/phar.1788. Epub 2016 Jul 22. PMID: 27318031.
[ 2 ] Keller SF, Mandell BF. Management and Cure of Gouty Arthritis. Med Clin North Am. 2021 Mar;105(2):297-310. doi: 10.1016/j.mcna.2020.09.013. Epub 2021 Jan 14. PMID: 33589104.
[ 3 ] Khanna PP, Khanna D, Cutter G, Foster J, Melnick J, Jaafar S, Biggers S, Rahman AKMF, Kuo HC, Feese M, Kivitz A, King C, Shergy W, Kent J, Peloso PM, Danila MI, Saag KG. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021 Aug;73(8):1523-1532. doi: 10.1002/art.41731. Epub 2021 May 19. PMID: 33750034; PMCID: PMC8324571.
[ 4 ] Nyborg AC, Ward C, Zacco A, Chacko B, Grinberg L, Geoghegan JC, Bean R, Wendeler M, Bartnik F, O'Connor E, Gruia F, Iyer V, Feng H, Roy V, Berge M, Miner JN, Wilson DM, Zhou D, Nicholson S, Wilker C, Wu CY, Wilson S, Jermutus L, Wu H, Owen DA, Osbourn J, Coats S, Baca M. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties. PLoS One. 2016 Dec 21;11(12):e0167935. doi: 10.1371/journal.pone.0167935. PMID: 28002433; PMCID: PMC5176304.
[ 5 ] Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). J Rheumatol. 2021 May;48(5):767-774. doi: 10.3899/jrheum.200460. Epub 2020 Sep 15. PMID: 32934137.
[ 6 ] Bessen SY, Bessen MY, Yung CM. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature. Semin Arthritis Rheum. 2019 Aug;49(1):56-61. doi: 10.1016/j.semarthrit.2018.11.006. Epub 2018 Dec 4. PMID: 30583886.